🇺🇸 FDA
Patent

US 8048418

Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 8048418 (Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/507